Deutsche Bank’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$27.5M Buy
925,919
+44,239
+5% +$1.32M 0.01% 767
2025
Q4
$33.7M Sell
881,680
-717,615
-45% -$23.3M 0.01% 746
2025
Q3
$38.2M Buy
1,599,295
+1,082,747
+210% +$20.4M 0.01% 685
2025
Q2
$7.64M Sell
516,548
-9,223
-2% -$153K ﹤0.01% 1084
2025
Q1
$9.42M Sell
525,771
-6,260
-1% -$127K ﹤0.01% 1027
2024
Q4
$9.27M Sell
532,031
-143,054
-21% -$2.53M ﹤0.01% 1049
2024
Q3
$9.44M Sell
675,085
-271,516
-29% -$2.83M ﹤0.01% 1028
2024
Q2
$7.78M Sell
946,601
-1,454,972
-61% -$9.8M ﹤0.01% 1080
2024
Q1
$18.5M Buy
2,401,573
+806
+0% +$6.8K 0.01% 836
2023
Q4
$21.6M Buy
2,400,767
+2,092,311
+678% +$15.2M 0.01% 782
2023
Q3
$2.76M Sell
308,456
-116,085
-27% -$1.64M ﹤0.01% 1233
2023
Q2
$6.52M Sell
424,541
-52,267
-11% -$951K ﹤0.01% 1145
2023
Q1
$10.7M Buy
476,808
+200,381
+72% +$4.26M 0.01% 944
2022
Q4
$5.81M Sell
276,427
-51,406
-16% -$1.09M ﹤0.01% 1160
2022
Q3
$8.08M Sell
327,833
-217,401
-40% -$5.62M ﹤0.01% 1027
2022
Q2
$13.2M Sell
545,234
-28,810
-5% -$725K 0.01% 903
2022
Q1
$14.8M Buy
574,044
+176,398
+44% +$4.68M 0.01% 933
2021
Q4
$12.3M Buy
397,646
+56,799
+17% +$1.6M 0.01% 1021
2021
Q3
$8.27M Sell
340,847
-1,082
-0.3% -$19.9K ﹤0.01% 1245
2021
Q2
$4.99M Sell
341,929
-104,640
-23% -$2.06M ﹤0.01% 1526
2021
Q1
$11.2M Buy
446,569
+2,288
+0.5% +$63.2K 0.01% 1141
2020
Q4
$12.1M Buy
444,281
+8,121
+2% +$190K 0.01% 958
2020
Q3
$8.05M Buy
436,160
+4,718
+1% +$91.7K 0.01% 1052
2020
Q2
$8.81M Buy
431,442
+13,095
+3% +$209K 0.01% 1027
2020
Q1
$6.1M Sell
418,347
-1,743
-0.4% -$26.2K 0.01% 1137
2019
Q4
$5.96M Sell
420,090
-36,446
-8% -$466K ﹤0.01% 1353
2019
Q3
$5.29M Sell
456,536
-156,256
-25% -$2.58M ﹤0.01% 1370
2019
Q2
$12.3M Sell
612,792
-166,983
-21% -$3.3M 0.01% 1238
2019
Q1
$17.6M Buy
779,775
+643,476
+472% +$14.2M 0.01% 1053
2018
Q4
$3.08M Sell
136,299
-819,818
-86% -$20.4M ﹤0.01% 2120
2018
Q3
$27.5M Buy
956,117
+64,949
+7% +$1.86M 0.01% 959
2018
Q2
$24.3M Sell
891,168
-156,403
-15% -$4.17M 0.01% 1063
2018
Q1
$23.4M Buy
1,047,571
+489,833
+88% +$11.7M 0.01% 1019
2017
Q4
$11.8M Sell
557,738
-117,716
-17% -$2.69M 0.01% 1373
2017
Q3
$16.8M Sell
675,454
-49,480
-7% -$1.09M 0.01% 1146
2017
Q2
$14.1M Sell
724,934
-92,428
-11% -$1.68M 0.01% 1155
2017
Q1
$15.1M Buy
817,362
+32,884
+4% +$643K 0.01% 1028
2016
Q4
$14.8M Buy
784,478
+161,149
+26% +$3.3M 0.01% 1024
2016
Q3
$13.9M Sell
623,329
-258,748
-29% -$4.93M 0.01% 1091
2016
Q2
$15.7M Buy
882,077
+320,583
+57% +$5.19M 0.01% 1046
2016
Q1
$7.67M Sell
561,494
-101,463
-15% -$1.54M 0.01% 1447
2015
Q4
$12.8M Sell
662,957
-9,282
-1% -$185K 0.01% 1174
2015
Q3
$13.6M Sell
672,239
-132,494
-16% -$3.92M 0.01% 1122
2015
Q2
$26.7M Buy
804,733
+126,749
+19% +$3.47M 0.02% 790
2015
Q1
$16.2M Buy
677,984
+290,561
+75% +$4.43M 0.01% 1048
2014
Q4
$4.74M Buy
387,423
+249,472
+181% +$2.58M ﹤0.01% 2000
2014
Q3
$1.24M Sell
137,951
-411,138
-75% -$4.84M ﹤0.01% 2868
2014
Q2
$6.45M Buy
549,089
+179,413
+49% +$2.43M ﹤0.01% 1640
2014
Q1
$7.84M Buy
+369,676
New +$5.68M 0.01% 1503

Other funds holding TVTX

Deutsche Bank's TVTX Position: Q1 2026 in Review

Deutsche Bank increased its Travere Therapeutics (TVTX) stake by 5% in Q1 2026, buying an estimated $1.32M and bringing the position to 925,919 shares worth $27.5M. The position accounts for 0.01% of the portfolio, ranked #767.

Deutsche Bank first reported a position in TVTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $38.2M in Q3 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Deutsche Bank held 925,919 shares of Travere Therapeutics worth $27.5M as of Q1 2026.
  • Deutsche Bank bought 44,239 Travere Therapeutics shares in Q1 2026, an estimated $1.32M.
  • Travere Therapeutics made up 0.01% of Deutsche Bank's portfolio in Q1 2026, its #767 holding.
  • Deutsche Bank first reported a position in Travere Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Deutsche Bank's Travere Therapeutics position peaked at $38.2M in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.